Patient selection for thoracic radiotherapy in extensive-stage small-cell lung cancer. (November 2017)

• Record Type: Journal Article
• Authors: Corkum, Mark T; Rodrigues, George B
• Is Part Of: Lung cancer management. Volume 6:Number 2(2017)
• Page Start: 47
• Page End: 53
• Publication Date: 2017-11
• Subjects: consolidative radiotherapy -- extensive-stage -- patient selection -- small-cell lung cancers; Lungs -- Cancer -- Periodicals; 616.99424
• DOI: 10.2217/lmt-2017-0006
• Languages: English
• ISSNs: 1758-1966

Abstract

Treatment of extensive-stage small-cell lung cancer remains a challenge with poor local control and overall survival. Chemotherapy is the mainstay of treatment, consisting of a combination of a platinum agent plus etoposide. The role of consolidative chest radiotherapy in extensive-stage small-cell lung cancer remains controversial. Two randomized clinical trials have been published demonstrating improved intrathoracic disease control with a small survival benefit, though interpretation and application of these results to clinical practice has been debated. These two trials examined different radiotherapy techniques and doses, with a third trial treating consolidative chest and oligometastatic disease having closed prematurely due to an interim analysis demonstrating treatment futility plus increased toxicity. Patients with residual intrathoracic disease after chemotherapy appear to benefit the most from consolidative chest radiotherapy, offering a potential tool to help select appropriate patients.